Chemically modified tetracycline (COL-3) improves survival if given 12 but not 24 hours after cecal ligation and puncture.
Sepsis can result in excessive and maladaptive inflammation that is responsible for more than 215,00 deaths per year in the United State alone. Current strategies for reducing the morbidity and mortality associated with sepsis rely on treatment of the syndrome rather than prophylaxis. We have been investigating a modified tetracycline, COL-3, which can be given prophylactically to patients at high risk for developing sepsis. Our group has shown that COL-3 is very effect at preventing the sequelae of sepsis if given before or immediately after injury in both rat and porcine sepsis models. In this study, we wanted to determine the "treatment window" for COL-3 after injury at which it remains protective. Sepsis was induced by cecal ligation and puncture (CLP). Rats were anesthetized and placed into five groups: CLP (n = 20) = CLP without COL-3, sham (n = 5) = surgery without CLP or COL-3, COL3@6h (n = 10) = COL-3 given by gavage 6 h after CLP, COL3@12h (n = 10) = COL-3 given by gavage 12 h after CLP, and COL3@24h (n = 20) = COL-3 given by gavage 24 h after CLP. COL-3 that was given at 6 and 12 h after CLP significantly improved survival as compared with the CLP and the CLP@24h groups. Improved survival was associated with a significant improvement in lung pathology assessed morphologically. These data suggest that COL-3 can be given up to 12 h after trauma and remain effective.
Halter
Jeffrey M
JM
Department of Surgery, SUNY Upstate Medical University, 750 E. Adams Street, Syracuse, NY 13210, USA.
Pavone
Lucio A
LA
Steinberg
Jay M
JM
Gatto
Louis A
LA
DiRocco
Joseph
J
Landas
Steve
S
Nieman
Gary F
GF
D000818:Animals; D002432:Cecum / Q000473:pathology / Q000601:surgery*; D004195:Disease Models, Animal; D008168:Lung / Q000473:pathology; D008297:Male; D011654:Pulmonary Edema / Q000378:metabolism; D011677:Punctures; D051381:Rats; D017207:Rats, Sprague-Dawley; D018805:Sepsis; D012772:Shock, Septic / Q000628:therapy*; D013754:Tetracyclines / Q000494:pharmacology*; D013997:Time Factors; D016896:Treatment Outcome
D013754:Tetracyclines; C117155:tetracycline CMT-3